Clinical Trials Logo

Nephrosis clinical trials

View clinical trials related to Nephrosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05599815 Withdrawn - Nephrotic Syndrome Clinical Trials

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Start date: January 2023
Phase: Phase 2
Study type: Interventional

A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

NCT ID: NCT04536181 Withdrawn - Clinical trials for Steroid-Sensitive Nephrotic Syndrome

Study of Initial Steroid Treatment in Young Children With Nephrotic Syndrome

Start date: January 1, 2021
Phase: Phase 3
Study type: Interventional

This study is a multicentric, prospective, randomized, double blind, placebo controlled trial compared the efficacy of 6 months vs. 3 months of initial prednisolone therapy in decreasing the incidence of FRNS with steroid-sensitive nephrotic syndrome in children age 1 year up to 6 years. Three months tapering prednisolone or placebo are administrated follow by open-label 3 months standard prednisolone therapy.The cumulative incidence of FRNS and adverse events for one year were evaluated in the 3-month and 6-month groups.

NCT ID: NCT04531865 Withdrawn - Clinical trials for Steroid-Dependent Nephrotic Syndrome

Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Start date: January 1, 2021
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of maintenance Mycophenolate Mofetil following single course of Rituximab in maintaining remission over 12 months among Children with frequently-relapsing or steroid-dependent nephrotic syndrome

NCT ID: NCT03408405 Withdrawn - Clinical trials for Steroid-Resistant Nephrotic Syndrome

ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children

ADRENL
Start date: June 2018
Phase: Phase 4
Study type: Interventional

We propose to study the use of purified porcine Acthar Gel (ACTHAR, Mallinckrodt Pharmaceuticals) for treatment of steroid resistance nephrotic syndrome (SRNS) in a prospective pilot study. We plan to enroll 25 children between the ages of 2 to 21 years. Children fulfilling strict inclusion criteria, whose parents agree to written informed consent after institutional IRB approval for the study, will be enrolled. Purified porcine Acthar Gel will be administered SQ to all children using a defined treatment protocol for a period of six months. Renal function, urine protein excretion, serum albumin levels, blood pressure and growth parameters will be monitored closely on all patients. Baseline urine protein excretion will be compared to end of treatment levels to determine successful response to therapy. There will be an 18 month enrollment period, 6 month treatment period and a 12 month follow-up period.

NCT ID: NCT02997150 Withdrawn - Clinical trials for Nephrotic Syndrome Steroid-Dependent

Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study

NIL-2 pilote
Start date: February 2017
Phase: Phase 2
Study type: Interventional

NIL-2 is a clinical trial designed to evaluate the efficacy and safety of low doses of Interleukin2 in the treatment of recently diagnosed, steroid dependent idiopathic nephrotic syndrome in children. Recent data suggest that Interleukin 2 could be an effective therapy via an increased production of regulatory T cells.